39856-52-5

Basic information

• Product Name: N5,N5-dimethylpyridine-2,5-diamine
• Synonyms: N5,N5-dimethylpyridine-2,5-diamine;2-Amino-5-dimethylaminopyridine;N5,N5-dimethyl-2,5-Pyridinediamine;N3,N3-Dimethylpyridine-3,6-diamine;5-dimethylamino-2-aminopyridine
• CAS NO: 39856-52-5
• Molecular Formula: C₇H₁₁N₃
• Molecular Weight: 137.18234
• EINECS: 254-658-0
• Product Categories: amine
• Mol File: 39856-52-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 261.3 °C at 760 mmHg
• Flash Point: 111.8 °C
• Appearance: /
• Density: 1.115 g/cm³
• Vapor Pressure: 0.0117mmHg at 25°C
• Refractive Index: 1.614
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: N5,N5-dimethylpyridine-2,5-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: N5,N5-dimethylpyridine-2,5-diamine(39856-52-5)
• EPA Substance Registry System: N5,N5-dimethylpyridine-2,5-diamine(39856-52-5)

Safety Data

• Hazardous Substances Data: 39856-52-5(Hazardous Substances Data)

Usage

General Description

N5,N5-Dimethylpyridine-2,5-diamine, also known as DMPDA, is a chemical compound with the molecular formula C7H11N3. It is a derivative of pyridine and is commonly used as a catalyst in organic synthesis and polymerization reactions. DMPDA is a versatile compound that has a wide range of applications, including in the production of pharmaceuticals, pesticides, and dyes. It is also used as a stabilizer for plastics, an additive in fuel and lubricants, and as a corrosion inhibitor. DMPDA is a colorless to pale yellow liquid with a strong odor, and it should be handled with care due to its potential health hazards and environmental impact.

InChI:InChI=1/C7H11N3/c1-10(2)6-3-4-7(8)9-5-6/h3-5H,1-2H3,(H2,8,9)

Upstream product

• 39856-50-3 5-bromo2-nitropyridine 
• 38772-04-2 dimethyl-(6-nitro-pyridin-3-yl)-amine 

Relevant articles and documents

Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors

CDK4/6 pathway is an attractive target for development of anti-cancer drugs. Herein, we reported the design and synthesis of a series of 4,5-dihydro-1H-pyrazolo [4,3-h]quinazoline derivatives as selective CDK4/6 inhibitors. Applied with the optimizing strategy to the initial scaffold, it is found that compound 13n is able to selectively inhibit CDK4 and CDK6 with IC50 values 0.01 and 0.026 μM, respectively. The compound showed good anti-proliferative activity when tested in a panel of tumor cell lines with CDK4/6 related mechanism of action, the results clearly suggest that compound 13n works much better than Ly2385219 which is a selective CDK4/6 inhibitor. This compound was also found to have favorable pharmacokinetic parameters. Taken together, compound 13n could be selected for further preclinical evaluation.

DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS

The present invention is related to a compound of formula (I): wherein R1, R2, R3, R4 and X are as defined herein, or an addition salt with an acid thereof, its pharmaceutical composition or use for treating or preventing diseases involving Nurr-1 nuclear receptors, also known as NR4A2, NOT, TINUR, RNR-1 and HZF3.

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.